WO1993014127A1 - Method and composition for heparin binding using polyaminocations covalently immobilised on polymeric surfaces with polyethylene oxide spacers - Google Patents
Method and composition for heparin binding using polyaminocations covalently immobilised on polymeric surfaces with polyethylene oxide spacers Download PDFInfo
- Publication number
- WO1993014127A1 WO1993014127A1 PCT/US1993/000678 US9300678W WO9314127A1 WO 1993014127 A1 WO1993014127 A1 WO 1993014127A1 US 9300678 W US9300678 W US 9300678W WO 9314127 A1 WO9314127 A1 WO 9314127A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pala
- peo
- heparin
- molecular weight
- pll
- Prior art date
Links
- 229920003171 Poly (ethylene oxide) Polymers 0.000 title claims abstract description 159
- 229920000669 heparin Polymers 0.000 title claims abstract description 144
- 229960002897 heparin Drugs 0.000 title claims abstract description 143
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 142
- 125000006850 spacer group Chemical group 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims description 22
- 229920000083 poly(allylamine) Polymers 0.000 claims abstract description 139
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims abstract description 63
- 229920000642 polymer Polymers 0.000 claims abstract description 35
- 239000000758 substrate Substances 0.000 claims abstract description 30
- 239000001913 cellulose Substances 0.000 claims abstract description 10
- 229920002678 cellulose Polymers 0.000 claims abstract description 9
- 230000007935 neutral effect Effects 0.000 claims abstract description 9
- 229920001222 biopolymer Polymers 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 30
- -1 poly(ethylene-vinyl alcohol) Polymers 0.000 claims description 7
- 229920001747 Cellulose diacetate Polymers 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 abstract description 40
- 239000008280 blood Substances 0.000 abstract description 40
- 229920002301 cellulose acetate Polymers 0.000 abstract description 21
- 239000003446 ligand Substances 0.000 abstract description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 14
- 108010017384 Blood Proteins Proteins 0.000 abstract description 4
- 102000004506 Blood Proteins Human genes 0.000 abstract description 4
- 239000012503 blood component Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000002202 Polyethylene glycol Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 125000003277 amino group Chemical group 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 125000002843 carboxylic acid group Chemical group 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920002635 polyurethane Polymers 0.000 description 5
- 239000004814 polyurethane Substances 0.000 description 5
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 230000002429 anti-coagulating effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940048914 protamine Drugs 0.000 description 4
- 229940014800 succinic anhydride Drugs 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003335 steric effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
- FIHZWZBEAXASKA-UHFFFAOYSA-N Anthron Natural products COc1cc2Cc3cc(C)cc(O)c3C(=O)c2c(O)c1C=CC(C)C FIHZWZBEAXASKA-UHFFFAOYSA-N 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000264877 Hippospongia communis Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000002296 pyrolytic carbon Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- PRZSXZWFJHEZBJ-UHFFFAOYSA-N thymol blue Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC(O)=C(C(C)C)C=2)C)=C1C PRZSXZWFJHEZBJ-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3675—Deactivation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/327—Polymers obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
Definitions
- compositions and methods for the removal of heparin from blood to minimize the risk of hemorrhagic complications More particularly, this invention relates to compositions consisting of a polymeric substrate which has been modified to contain polycation ligands having primary amino groups which are covalently bonded to the substrate through a polyethyleneoxide type spacer and to methods of removing heparin from blood or other solutions by contacting heparinized solution with said compositions.
- Heparin is a powerful anticoagulant which is often administered during surgical or other procedures to prevent the formation of clots.
- AT III Antithrombin III
- AT III is a plasma glycoprotein with molecular weight approximately 58,000.
- AT III binds with thrombin very tightly at a 1:1 stoichiometric ratio, which blocks the active site on thrombin and prevents it from interacting with fibrinogen.
- the inhibition rate of thrombin with AT III is low in absence of heparin.
- Heparin dramatically accelerates the rate of thrombin inactivation up to 2000-fold.
- Clinically used heparin can be separated into two distinct fractions according to their affinity for AT III.
- heparin Approximately 33% of heparin has a high affinity for AT III, which has potent anticoagulant activity (up to 90% of the activity of the unfractionated heparin). A low-affinity heparin binds to the same site on AT III, but with approximately 1000 times lower affinity.
- Heparin Although anticoagulation is the major pharmacological activity, heparin has many other functions. Heparin inhibits the proliferation of vascular smooth muscle cells and renal mesengial cells, suppresses the delayed-type hypersensitivity, and inhibits angiogenesis. Other pharmacological functions of heparin include antithrombotic effect, antibacterial, antivirus, and antitumor angiogenesis, particularly in combination with cortisone. Although it has been clinically observed that heparin may induce thrombocytopenia, in vitro studies have shown that normal heparin enhances the release of platelets. Moreover, various heparin-binding growth factors can be purified with heparin affinity chromatography.
- Heparin has been extensively used in many clinical applications, including cardiac surgery, peripheral vascular surgery, dialysis, autotransfusion, transplantation, the treatment of pulmonary embolism, disseminated intravascular coagulation, and venous thrombosis. The dosage is dependent on the type of application. Heparin has also been used as a prophylactic agent against deep vein thrombosis. Heparin is also of value in the treatment of thromboembolic disorders, such as pulmonary embolism and arterial thrombosis.
- heparin is immobilized onto polymers to form nonthrombogenic surfaces to achieve a localized anticoagulant effect at the polymer blood interface.
- heparin has been fixed onto polymers with positive charges by forming a stable complex or by being covalently bound thereto via a spacer grouping.
- the immobilized heparin on the surface may then be released into blood by ion exchange, subsequently, the released free heparin interacts with AT III and thus exerts its anticoagulant effect.
- heparin increases the blood compatibility of the polymer for long-term biomedical applications, particularly when bound through an appropriate spacer grouping.
- Polymers bearing positive charges have been used to anchor heparin onto surfaces and have shown good long term blood compatibility.
- charged polymers such as poly-4-vinylpyridine, Fourt et al., Adv. Chem . Ser. 87, 187 (1968); poly(amidoamine) grafted polyurethane (PUPA), Azzuuoli et al., Biomaterials 8, 61 (1987); and polyvinylchloride grafted with both polyethyleneglycol monomethacrylate and quarternized dimethylaminoethyl methacrylate (Anthron), Nagaoka et al., J. Biomater. Appl . 4 , 3 (1989), have been reported to form a stable complex with heparin.
- the second means where binding of negatively charged heparin onto polymeric surfaces has been applied in the biomedical field in the area of heparin neutralization where heparin is removed from blood onto the polymer surface by binding.
- heparin can be dangerous since less than desired concentrations of heparin in blood increases the likelihood of unwanted coagulation after surgery or when blood comes into contact with biopolymeric surfaces thus forming unwanted blood clots in the arteries and veins. It is well documented that most synthetic polymers activate blood coagulation when contact is made between blood and the polymer surface. Therefore, administered heparin is necessary to minimize clotting. This heparin may be present in the blood at relatively high concentrations during contact with polymeric surfaces such as during extracorporeal circulation to prevent clotting in the extracorporeal circuit. Excessive heparin in blood needs to be neutralized at the end of extracorporeal circulation due to the risk of hemorrhagic complications.
- protamine a cationic protein
- Anido et al. Am . J. Clin . Pathol . 76, 410 (1981).
- protamine also has undesirable side effects, including the risk of anaphylactic reactions in some patients.
- protamine immobilized cellulose hollow fiber Kim et al., Trans . Am. Soc . Artif. Intern.
- Cationic polyelectrolyte surfaces proposed for binding and removal of heparin, include the use of triethylaminoethyl cellulose powder (Heparsorb, Organon Teknika, Durham, NC) and poly-L-lysine bound agarose (Sepharose 4B), Mohammad et al., Thromb . Res . , 20, 599 (1980)
- prior art methods have demonstrated the degree of heparin removal that is desired is not sufficient or takes too long to accomplish.
- One of the reasons for polycationic surfaces not being as effective as might be desired has to do with variables affecting heparin binding onto polycationic surfaces.
- electrostatic attractions exist between the positively charged polycations and the negatively charged heparin.
- steric accessibility of heparin onto polycationic interfaces is also an important consideration.
- heparin binding onto polycationic surfaces may be controlled by the balance between the electrostatic attraction and steric accessibility factors.
- An additional object of this invention is the formation of a polymeric substrate containing polycationic ligands having primary amino groups and preferably those selected from the group consisting of polylysine (PLL), polyallylamine (PALA) or polyvinylamine (PVA) bonded through a polyethylene oxide (PEO) spacer grouping to a biocompatible polymeric substrate.
- PLL polylysine
- PVA polyallylamine
- PVA polyvinylamine
- Another object of this invention is to provide a method for the binding and/or removal of heparin in blood by contacting the blood with a polymeric substrate containing polycationic ligands selected from the group consisting of polylysine (PLL), polyallylamine (PALA) or polyvinylamine (PVA) bonded through a polyethylene oxide (PEO) spacer grouping to a biocompatible polymeric substrate.
- PLL polylysine
- PVA polyallylamine
- PVA polyvinylamine
- An additional object to provide a method of removing heparin from blood with a minimum loss of the plasma proteins and other components of blood.
- compositions consisting of a polymeric substrate which has been modified to contain polycations such as polyallylamine (PALA), poly- L-lysine (PLL) or polyvinylamine (PVA) covalently bonded to the substrate through a polyethyleneoxide type spacer effectively removes heparin from blood with little or no loss of plasma proteins or other blood components.
- polycations such as polyallylamine (PALA), poly- L-lysine (PLL) or polyvinylamine (PVA) covalently bonded to the substrate through a polyethyleneoxide type spacer.
- PALA or PLL is most preferable with PALA being the polycation determined to be best suited for purposes of this invention.
- the polycationic ligand when covalently bound to a suitable polymeric substrate via a polyethylene oxide (PEO) spacer, provides a solution like polycationic interfacial environment.
- the solution like conditions are due to the increased mobility of the polycation ligand as a result of the PEO spacer.
- the flexibility of the polycation attributed to the presence of the spacer at the interface of the polymer minimizes the steric inaccessibility of the heparin thereby improving the binding characteristics.
- any suitable polycation ligand rich in NH 2 groups can theoretically be utilized to bind heparin, it has been found preferable to use either polyallylamine (PALA) or poly-L-lysine (PLL) as the ligand.
- PEO polyallylamine
- PLL poly-L-lysine
- a polymer substrate having free hydroxy groups such as cellulose or cellulose diacetate.
- the PEO molecule may be derivatized by functional groups, as will be discussed more in detail below, to maximize the ability of the PEO to covalently link the ligand with the polymeric substrate.
- Heparin is removed from blood or other fluids by bringing the fluids in contact with the polymeric substrate material containing immobilized polycations with PEO spacers where heparin is adsorbed by the material. Heparin can be released from the immobilized polycations by treatment with a basic solution, thereby allowing the material to be reused when practical.
- the substrate containing the immobilized polycationic ligands connected via the PEO spacers must present a large surface area to the blood or other fluid in order to maximize the opportunity for the heparin to come into contact with the positively charged ligands.
- the substrates can be in the form of films, beads, honeycombs, coated surfaces, strands, filaments, and the like.
- the rate of heparin binding is somewhat dependant on controlling parameters such as blood flow rates, concentration of heparin in blood and exposure time of heparinized blood to the binding substrate.
- the binding of heparin onto the polycationic surfaces grafted to the polymer surface via PEO spacers of molecular weight of between about 600 and 8,000 seems to depend on the balance of several factors such as the size of the polycation ligand, the molecular weight of the PEO spacer, the mobility of the PEO and the chain length of the PEO-polycation at the interface.
- PALA having molecular weights ranging from about 8,500 to about 65,000 is suitable for use in the present invention.
- PALA is categorized as PALA(L) for a low molecular weight PALA having a molecular weight of between about 8,500 and 11,000 and PALA(H) for a high molecular weight PALA having a molecular weight range of about 50,000 to 65,000.
- a composition consisting of low molecular weight PALA (M.W. 8500) immobilized onto a biopolymer surface with a PEO spacer (M.W. 3400) is believed to provide optimal heparin binding capacity with decreased protein adsorption.
- heparin removal from polycationic containing substrates is primarily due to the charge interaction between the polyanionic heparin and the polycations. No hemolysis or clotting is observed in circulating blood, suggesting the such a removal system will not cause adverse effects on blood.
- the system is also effective in removing heparin from aqueous solutions other than blood.
- substrate any suitable biopolymer having hydroxy groups to which the polycation may be covalently bonded, either directly or through a PEO type spacer.
- the substrate may be represented by the following formula:
- Biomedical polymers include, but are not limited to, such hydroxy containing materials as cellulose and derivatives such as cellulose diacetate (CA), poly (ethylene-vinyl alcohol) copolymers
- PEVAL polyethylene glycol
- agarose agarose
- biomedical polymers such as polycarbonates, silicones, acetals, polyesters, polytetrafluroethylene, polyurethane, pyrolytic carbon, nylon or other polyamides, polyacrylonitrile, polyethersulfone and the like by devising reaction sequences and linkages which provide for covalent attachment of polycations to these surfaces.
- polycation is meant a polymeric molecule having a repeating segment containing primary amino groups on the side chain and which is positively charged at neutral pH. These may be generically referred to as polyaminocations (PAC). As stated, polyallylamine (PALA), poly-L-lysine (PLL)) and polyvinylamine (PVA) are preferred with PALA and PLL being most preferred.
- PAC polyaminocations
- PLL is a polypeptide of the formula:
- n is an integer of between about 200 and 240 and which becomes cationic when the e-amino gruups on the side chain become fully protonated. Its ionization depends upon the pH of the medium in which it is contained but is known to form electrostatic interactions with heparin at a neutral pH.
- the positive charges of PLL per molecule can be adjusted by selecting different molecular PLL weights. The molecular weight range of PLL will generally vary between about 40,000 and 50,000.
- PALA is a recently commercialized polymer with primary amino groups as pendant side chains having the formula:
- m is an integer of between about 78 to 500, having a molecular weight of between about 8,500 and 65,000 and is prepared from polymerization of a monoallylammonium salt initiated by an azo compound.
- PALA is obtained commercially as a HCl salt wherein the HCl is removed by increasing the pH with NaOH.
- PALA has a higher positive charge density than PLL.
- PEG poly(ethylene glycol)
- PEO poly (ethylene oxide)
- n is an integer of between about 13 and 180.
- PEO is extremely water soluble.
- Low molecular weight PEO (less than 600) is a viscous fluid at room temperature. As the molecular weight increases, PEO becomes a waxy solid and morphology changes from amorphous to crystalline. PEO-water interaction is found to increase sharply with increasing molecular weight until a weight of about 3400 is reached and then remains constant within the 3400-20000 molecular weight range.
- spacer grouping it has been found that the chain mobility of PEO increases with increasing molecular weight up to about 4,000.
- PALA and PLL were both immobilized on PEVAL copolymer covalently using cyanogen bromide as a coupling agent.
- Cellulose diacetate and cellulose hollow fibers could also be used because each of these materials have hydroxyl groups available after proper treatment which can be activated by BrCN. Therefore, the amino groups of PALA and PLL can be coupled directly with the hydroxyl groups on these polymeric supports.
- the imidocarbonate of Formula 4 is then reacted with either PLL or PALA in an aqueous solution to covalently link a primary amino group from a pendant PLL or PALA chain with the polymer surface as follows in
- the PLL or PALA polycation When the PLL or PALA polycation is covalently immobilized on the polymer surface, it is relatively rigid and not laterally movable due to the intramolecular and intermolecular charge repulsions.
- the relatively low binding of heparin on polycations rigidly bound may be ascribed to the steric inaccessibility of heparin into the root part of the relatively rigid polycationic interface. Therefore, heparin may not bind efficiently on polycationic directly immobilized on to polymeric surfaces.
- PALA or PLL are coupled directly onto a poly(ethylene-vinyl alcohol) (PEVAL) surface using BrCN as a coupling reagent under exactly the same experimental conditions
- PALA immobilized surface (Formula 6) demonstrates a heparin binding capacity which is about 1.3 times that of PLL (Formula 5) which is believed to be due to the higher charge density of PALA per molecule when compared with PLL.
- Heparin binding of PALA was 0.71 ⁇ 0.08 ⁇ g/cm 2 and of PLL was 0.52 ⁇ 0.19 ⁇ g/cm 2 .
- the primary factors affecting heparin binding onto polycationic surfaces are electrostatic attractions between the positively charged surfaces and the negatively charged heparin, and steric accessibility of heparin into polycationic interfaces.
- the polycation When a polycation is covalently immobilized directly onto a polymer surface, the polycation is relatively rigid and not laterally movable due to the intramolecular and intermolecular charge repulsions.
- heparin binding onto polycationic surfaces may be enhanced by the balancing of the electrostatic binding and steric accessibility factors. It has been found that the heparin binding efficiency on polycation- immobilized surfaces is increased if the effect of the steric inaccessibility is minimized and a solution like polycationic interfacial environment is provided.
- Polyethylene glycol also referred to herein as polyethylene oxide "PEO"
- PEO polyethylene oxide
- the PEO provides a larger intermolecular gap between the polycations at the interface of the polymer surface and therefore minimizes the steric inaccessibility. Therefore, the binding properties of heparin are increased when PEO spacer molecules are inserted between the surface and the polycations.
- the heparin removal system is formed by reacting a polymeric surface containing free hydroxy groups, preferably with a PEO molecule which has been derivatized to form a diacid thereby creating an ester linkage between the hydroxy groups of the surface and the carboxylic acid group of the diacid.
- PEO may be derivatized to form diacids by : 1) the reaction of polyethylene oxide with succinic anhydride as shown in Formula 7; 2) the reaction of an alkoxide of polyethylene oxide with 2-halo-alkyl acetate as shown in Formula 8; and 3) the reaction of polyethylene oxide with an alkylene diacid such as azelaic acid as shown in Formula 9.
- HO-(-CH 2 CH 2 O-)- n H + - O - n 50-100
- diacids may be generically represented by a single formula as seen in Formula 10 as follows:
- the diacid PEO intermediate as represented by Formula 10 is first grafted onto the surface of a polymer, preferably one containing OH groups (Formula 1), using an agent such as 1,3-dicyclohexylcarcodiimide (DCC) to esterify the carboxylic acid groups of the diacid derivatized PEO with the hydroxyl group of the polymer surface according to following sequence:
- DCC 1,3-dicyclohexylcarcodiimide
- the esterified PEO grafted onto the polymer surface as represented by Formula 11, then has polycations, such as PLL or PALA, immobilized to the polymer by reacting the -COOH at the opposing end of the PEO with the polycation using an agent such as (3- dimethlyamino-propyl)carbodimide (EDC).
- EDC (3- dimethlyamino-propyl)carbodimide
- the amount of polycation in the reaction solution will be in excess resulting in only one amino group of PLL or PALA per molecule reacting with each COOH group on the surface.
- This reaction sequence is represented as follows resulting in PLL or PALA immobilized compositions represents by Formulas 12 and 13 as follows:
- the final product formed contains polylysine (PLL) or polyallylamine (PAPA) separated from the surface by a spacer molecule of PEO.
- PLL polylysine
- PAPA polyallylamine
- any polycation having free amino groups which can be covalently bonded to the PEO spacer may be a suitable agent and is within the scope of this invention. Therefore, the compositions of the invention may be broadly defined by the following formula 14:
- PAC stands for any suitable polyaminocation and preferably one selected from the group consisting of polyallyl amine (PALA), poly-L-lysine (PLL) or polyvinlyamine.
- PVA polyallyl amine
- PLL poly-L-lysine
- polyvinlyamine polyvinlyamine
- the material upon which the spacer molecule is bonded can be any substance that has free hydroxy groups to which the PEO diacid intermediate can be esterified, for example, cellulose, cellulose acetate or a poly(ethylene vinyl alcohol) copolymer.
- the formula representing the compositions of this invention may be further simplified for purposes of claiming.
- the structures of the PEO spacer, and the PALA and PLL ligands are given in detail above. All have certain repeating units within their respective molecular structures and hence, with the formulas established, it is the molecular weights of these units which determines their functionality in the binding of heparin. Therefore the following formula will be referred to in the claims:
- Substrate-OC-PEO-CNH-PAC where Substrate is the same as Formula 1, -OC(O)-PEO- C(O)- has the same meaning as the PEO diacid of Formula 10 and -NH-PAC is the polyaminocation ligand and is preferably the PLL of Formula 2 or the PALA of Formula 3.
- -NH-PAC is the polyaminocation ligand and is preferably the PLL of Formula 2 or the PALA of Formula 3.
- This examples describes the derivatization of PEO with succinic anhydride to prepare PEO derivatives having carboxyl end groups according to the reaction sequence shown in Formula 7.
- the hydroxyl end groups of PEO (having molecular weights of 600, 2000, 3400, and 8000) were reacted with succinic anhydride in dioxane using 4-Dimethylaminopyridine (DMAP) and triethylamine (TEA) as catalysts according to the above reaction sequence.
- DMAP 4-Dimethylaminopyridine
- TAA triethylamine
- Succinic anhydride (20 mmol), 4- Dimethylaminopyridine (10 mmol) and triethylamine (TEA) (10 mmol) were dissolved in 20 ml of dioxane and added to a solution of 5 mmol of polyethylene oxide (PEO) (10 mmmol of OH groups) in 50 ml of dioxane. The mixture was stirred for 12 hr at 60° C. Most of the dioxane was then removed by a rotavapor. The residue was dissolved by dichloromethane and precipitated by ether. The products were dissolved and precipitated twice from dichloromethane/ether and then vacuum dried.
- PEO polyethylene oxide
- the terminal carboxylic acid groups of polyethylene oxide (PEO) diacids was determined by non-aqueous titration. PEO diacids (5 x 10 -4 mol) were dissolved in dioxane and titrated by sodium methoxide (0.1 N) in methanol-benzene (2.8) using 0.2% thymol blue as an indicator. The pure polyethylene oxide (PEO) in dioxane was used as a blank. The amount of sodium methoxide consumed by PEO diacid gave the information on the amount of carboxylic acid groups at two ends of polyethylene oxide (PEO).
- This example describes the preparation of a cellulose acetate substrate to which is attached the PEO-diacid spacer prepared according to Example 1.
- Cellulose acetate was dissolved in acetone to make a 10% solution.
- a casting knife was used to make a film with 0.8 mm thickness on a glass plate and allowed to air dry.
- the dried cellulose film was peeled off by rinsing the plate with distilled water.
- the cellulose acetate (CA) film (1000 cm 2 ) was immersed in dichloromethane:toluene solvent (5:5) overnight, then 9x10 -4 mol of PEO diacid of Example 1 and 9X10 -1 mol of 4-dimethylaminopyridine (DMAP) were added into the solution and stirred at 4°C for one hour.
- a 5 ml aliquot of 9X10 -4 mole of DCC in dichloromethane:toluene (5:5) was added dropwise to the reaction mixture and stirred for an additional 1 hour at 4°C. The whole solution was moved to 22 °C and allowed to stand for 48 hr.
- the amount of PEO coupled onto CA film surfaces was determined by acid-base back titration of its free end of carboxylic acid.
- the coupled film was thoroughly washed with distilled water and then immersed in distilled water (10 ml).
- Sodium hydroxide (0.01 N) was added to adjust the pH above 7.0.
- the solution and film were titrated potentiometrically with 0.01 N hydrochloric acid and the pH was monitored by a Corning pH Meter.
- CA film without PEO was used as blank.
- the amount of HCl consumed by PEO grafted film between the second equivalent point subtracted from the amount of HCl used by the blank at the same pH gave the amount of carboxylic acid groups, hence the PEO content on CA film.
- the results are shown in the table in following Example 3.
- This example describes the reaction of polyallyl amine with the CA-PEO film formed in Example 2.
- CA-PEO-COOH film prepared as described above (1000 cm 2 ) was immersed in water.
- PALA (2 x10 -4 mol) was added into the film suspension and stirred at 4°C for 1 hr.
- EDC 2.5x10 -4 mol
- the solution was then stirred for an additional 1 hr. at 4°C.
- the whole solution was moved to 22°C and allowed to stand for 24 hr.
- Two additional volumes of EDC were added to the solution at 3 and 6 hr during the reaction. After the reaction was completed, the CA-PEO-PALA films were washed with distilled water.
- the CA film contained immobilized PALA connected to the film surface via PEO spacers as shown in Formula 13. Both low molecular weight PALA(L) and high molecular weight PALA(H) were immobilized with varying PEO molecular weight spacers.
- the content of amino groups from PALA immobilized on the surface was determined by acid-base potentiometric back titration and also by spectroscopy analysis. At pH ⁇ 7, all the -NH 2 groups are changed to - NH 3 + which can be potentiometrically titrated by NaOH. The difference in the amounts of NaOH used between the CA-PEO-PALA and a blank CA gives the amounts of the amino groups on the surface.
- the results, measured in surface concentrations of 10 -8 mole/cm 2 are shown in the following table:
- the amount of amino groups on PALA(H) immobilized surfaces is about 2-3 times higher than that on PALA(L) surfaces.
- a similar procedure to that described above can be used to immobilize PLL onto a CA-PEO film to prepare a product as shown in Formula 12.
- CA-PEO-PALA films (240 cm 2 ) were placed in 10 ml of 40 ⁇ g/ml heparin solution (0.1 N Sodium carbonate buffer solution or saline) with shaking for 1 hr. The difference of heparin amount before and after binding gave the net amount heparin bound on the surfaces.
- CA-glutaric acid-PALA films was also evaluated as a control and compared with CA-PEG-PALA surfaces. The glutaric acid spacer did not provide sufficient linkage space to have any affect on the binding capacity of the PALA.
- the amount of heparin on PALA(L) (molecular weight 8,500) immobilized with PEO spacers of varying molecular weight is shown in the following table with a concentration of immobilized PALA on the cellulose acetate surface being given in concentrations of 10 -10 mole/cm 2 :
- the amount of heparin on PALA(H) (molecular weight 50,000) immobilized with PEO spacers of varying molecular weight is shown in the following table with a concentration of immobilized PALA on the cellulose acetate surface being given in concentrations of 10 -11 mole/cm 2 :
- the PEO-PALA(L) interface was more solution like and less steric restriction than the PEO- PALA(H) interface.
- the PEO-PALA(L)-immobilized surfaces when glutaric acid was used to link PALA(L) with the CA film, no spacer effect was considered due to its short chain. Therefore, heparin binding efficiency was low due to the rigid PALA(L) at the interface.
- PEO(0.6K) as a spacer, despite the increased mobility of PALA(L) at the interface, the short chain length of PALA(L)-PEO (0.6K) at the interface could not enhance heparin binding. This minimum chain length requirement at the interface may be ascribed to the relatively large size of the heparin macromolecule.
- CA-PEO (2K) -PALA(L) film was immersed in 1 ml of the heparinized bovine plasma or whole blood (40 ⁇ g heparin/ml blood, 2% of 35 S-labeled heparin). After incubation for 1 hr, the film was rinsed with distilled water and 1 ml of NaOH solution was added. After 5 min shaking, CytoScint cocktail (15ml) was added. The solution was mixed well on a vortex shaker and the radioactivity was counted.
- CA- PEO (2K)-PALA(L) film was immersed in 1:10 diluted serum solution containing heparin (40 ⁇ g heparin/ml serum solution). After incubation for 1 hr., 0.5ml of solution was taken out for Azure II colorimetric assay.
- the amount of heparin bound on CA-PEO(2K)-PALA(L), CA-PEO(2K)-PALA(H), CA-glutaric acid-PALA(L), and CA- glutaric acid-PALA(H) membranes in bovine serum was compared with the corresponding heparin binding amount in aqueous solution. The comparison did not show significant difference between these two media.
- the amount of heparin binding in bovine plasma or whole blood was determined by counting the radioactivity of 35 S-heparin on the film.
- the amount of heparin bound on the CA-PEO(2K)-PAL-(L) film from plasma or whole blood was compared with the corresponding heparin bound amount in PBS using tracer 35 S-heparin, no significant differences in heparin binding amount among the three media were observed.
- the data shows blood components do not affect heparin binding on CA-PEO-PALA surfaces.
- Iodine-125 labeled bovine albumin was used as a model protein to study protein adsorption on CA-PEO-PALA surfaces using low molecular weight PALA and PEO spacers varying in molecular weight of from 600 (0.6K) to 8,000 (8K).
- the concentration of albumin in serum was determined by the bromcresol green method.
- PALA and PLL are structurally similar in having primary amino groups on the side chain and both being positively charged at neutral pH.
- PALA has a higher charge density per molecule than PLL due to the smaller repeat unit.
- Empirical results show that both PALA and PLL have similar heparin binding capacities.
- Comparison of average pKa of PALA and PLL indicates that the basic strength of PALA is slightly lower than that of PLL but the difference was not significant.
- the repulsive interactions of the intramolecular amino groups on the PALA chain is greater than that of PLL which may be attributed to the higher charge density per molecule of PALA than PLL.
- the greater intramolecular force between functional amino groups on PALA also translates into the fact that changes of pKa value of PALA is more sensitive than to the changes of pH than with PLL.
- Another similarity with PALA and PLL is that the degree of ionization is similar at about neutral pH.
- the pKa of PLL is lightly higher than that of PALA inferring that he interaction between PLL and polyanions such as heparin may be somewhat stronger than that of PALA.
- the higher positive charge density of PALA per molecule when compared with PLL suggests that PALA may actually bind more heparin than PLL.
- the criteria for selecting a polycation as a heparin binding reagent are (a) capability of binding heparin, (b) functional groups which can be covalently grafted onto polymeric surfaces and (c) commercial availability at a reasonable price.
- Any polycation having primary amino groups is considered to be a candidate for use in this invention due to the likelihood of various chemical reactions with the free amino groups.
- Inclusive of polycations which are currently commercially available and have free amino groups are PLL, PALA and PVA. The high price of PLL limits its practical usage.
- the terminal amino groups which can be covalently grafted onto polymeric surfaces
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
Compositions having formula (I) where Substrate represents any suitable biopolymer to which polycations may be covalently bonded through a spacer grouping; -OC(O)-PEO-C(O)- is a polyethylene oxide polymer having a molecular weight of between about 600 and 8000; and -NH-PAC represents any suitable polyaminocation which contains a positive charge at a neutral pH and effectively removes heparin from blood with little or no loss of plasma proteins or other blood components. The use of polyallylamine or poly-L-lysine as the polyaminocation is most preferable with polyallylamine being the polycation determined to be best suited for purposes of this invention. The polycationic ligand, when covalently bound to a suitable polymeric substrate via a polyethylene oxide (PEO) spacer, provides a solution like polycationic interfacial environment. The solution like conditions are due to the increased mobility of the polycation ligand as a result of the PEO spacer. The flexibility of the polycation attributed to the presence of the spacer at the interface of the polymer minimizes the steric inaccessibility of the heparin thereby improving the binding characteristics. The substrate upon which the spacer molecule is bonded can be any substance that has free hydroxy groups to which the PEO diacid intermediate can be esterified and include cellulose or cellulose acetate.
Description
METHOD AND COMPOSITION FOR HEPARIN BINDING USING POLYAMINOCATIONS COVALENTLY IMMOBILIZED ON POLYMERIC SURFACES WITH POLYETHYLENE OXIDE SPACERS
Background of the Invention
This invention relates to compositions and methods for the removal of heparin from blood to minimize the risk of hemorrhagic complications. More particularly, this invention relates to compositions consisting of a polymeric substrate which has been modified to contain polycation ligands having primary amino groups which are covalently bonded to the substrate through a polyethyleneoxide type spacer and to methods of removing heparin from blood or other solutions by contacting heparinized solution with said compositions.
Heparin is a powerful anticoagulant which is often administered during surgical or other procedures to prevent the formation of clots.
The anticoagulant properties of heparin have been demonstrated to be associated with heparin binding to Antithrombin III (AT III). AT III is a plasma glycoprotein with molecular weight approximately 58,000. AT III binds with thrombin very tightly at a 1:1 stoichiometric ratio, which blocks the active site on thrombin and prevents it from interacting with fibrinogen. However, the inhibition rate of thrombin with AT III is low in absence of heparin. Heparin dramatically accelerates the rate of thrombin inactivation up to 2000-fold. Clinically used heparin can be separated into two distinct fractions according to their affinity for AT III. Approximately 33% of heparin has a high affinity for AT III, which has potent
anticoagulant activity (up to 90% of the activity of the unfractionated heparin). A low-affinity heparin binds to the same site on AT III, but with approximately 1000 times lower affinity.
Although anticoagulation is the major pharmacological activity, heparin has many other functions. Heparin inhibits the proliferation of vascular smooth muscle cells and renal mesengial cells, suppresses the delayed-type hypersensitivity, and inhibits angiogenesis. Other pharmacological functions of heparin include antithrombotic effect, antibacterial, antivirus, and antitumor angiogenesis, particularly in combination with cortisone. Although it has been clinically observed that heparin may induce thrombocytopenia, in vitro studies have shown that normal heparin enhances the release of platelets. Moreover, various heparin-binding growth factors can be purified with heparin affinity chromatography.
Heparin has been extensively used in many clinical applications, including cardiac surgery, peripheral vascular surgery, dialysis, autotransfusion, transplantation, the treatment of pulmonary embolism, disseminated intravascular coagulation, and venous thrombosis. The dosage is dependent on the type of application. Heparin has also been used as a prophylactic agent against deep vein thrombosis. Heparin is also of value in the treatment of thromboembolic disorders, such as pulmonary embolism and arterial thrombosis.
As a polyanion, many properties and applications of heparin are associated with electrostatic interactions. Binding of negatively charged heparin onto polymeric surfaces has been applied in the biomedical field in two major ways.
First, heparin is immobilized onto polymers to form nonthrombogenic surfaces to achieve a localized anticoagulant effect at the polymer blood interface. As
a well known anticoagulant, heparin has been fixed onto polymers with positive charges by forming a stable complex or by being covalently bound thereto via a spacer grouping. In the case of charged polymers, the immobilized heparin on the surface may then be released into blood by ion exchange, subsequently, the released free heparin interacts with AT III and thus exerts its anticoagulant effect. In the case of being covalently bound to a polymer surface, heparin increases the blood compatibility of the polymer for long-term biomedical applications, particularly when bound through an appropriate spacer grouping.
Polymers bearing positive charges have been used to anchor heparin onto surfaces and have shown good long term blood compatibility. For example, charged polymers such as poly-4-vinylpyridine, Fourt et al., Adv. Chem . Ser. 87, 187 (1968); poly(amidoamine) grafted polyurethane (PUPA), Azzuuoli et al., Biomaterials 8, 61 (1987); and polyvinylchloride grafted with both polyethyleneglycol monomethacrylate and quarternized dimethylaminoethyl methacrylate (Anthron), Nagaoka et al., J. Biomater. Appl . 4 , 3 (1989), have been reported to form a stable complex with heparin.
Polyurethane surfaces modified by polyethylene oxide (PEO) and then reacted with heparin have displayed enhanced blood compatibility due to the synergistic effects of PEO and heparin. See Han et al., Evaluation of Blood Compatibility of PEO Grafted and Heparin Immobilized Polyurethanes, J. Biomed . Matr. Res . : Appl . Biomat . 23(A2), 211-228 (1989); Han et al., Preparation and Surface Characterization of PEO-grafted and Heparin- immobilized Polyurethanes, J . Biomed . Matr . Res . : Appl . Biomat . 23 (Al), 87-104 (1989); and Park et al., J. Biomed . Matr . Res . , 22, 977-992 (1988). The heparin in these applications enhances the blood compatibility of the polymer and is not released into the blood. This use extends only to localized surface effects and does not
provide anticoagulant properties to blood in the surgical field of use.
The second means where binding of negatively charged heparin onto polymeric surfaces has been applied in the biomedical field in the area of heparin neutralization where heparin is removed from blood onto the polymer surface by binding.
The administration of inadequate doses of heparin can be dangerous since less than desired concentrations of heparin in blood increases the likelihood of unwanted coagulation after surgery or when blood comes into contact with biopolymeric surfaces thus forming unwanted blood clots in the arteries and veins. It is well documented that most synthetic polymers activate blood coagulation when contact is made between blood and the polymer surface. Therefore, administered heparin is necessary to minimize clotting. This heparin may be present in the blood at relatively high concentrations during contact with polymeric surfaces such as during extracorporeal circulation to prevent clotting in the extracorporeal circuit. Excessive heparin in blood needs to be neutralized at the end of extracorporeal circulation due to the risk of hemorrhagic complications. Usually this is achieved by administration of protamine, a cationic protein, Anido et al., Am . J. Clin . Pathol . 76, 410 (1981). However, protamine also has undesirable side effects, including the risk of anaphylactic reactions in some patients. To circumvent this problem, protamine immobilized cellulose hollow fiber, Kim et al., Trans . Am. Soc . Artif. Intern.
Organs, 35, 644 (1989), and protamine grafted glycidyl methacrylate gel-cellulose, Hou et al., Artif . Organs,
14, 436 (1990), have been developed.
Excessive heparin in the blood can be attracted and removed by electrostatic interactions with polycationic surfaces. Cationic polyelectrolyte surfaces proposed for binding and removal of heparin, include the use of
triethylaminoethyl cellulose powder (Heparsorb, Organon Teknika, Durham, NC) and poly-L-lysine bound agarose (Sepharose 4B), Mohammad et al., Thromb . Res . , 20, 599 (1980)
Heparin ionically binds with the polycationic surfaces after exposure to blood and thus is removed from the blood. However, prior art methods have demonstrated the degree of heparin removal that is desired is not sufficient or takes too long to accomplish. One of the reasons for polycationic surfaces not being as effective as might be desired has to do with variables affecting heparin binding onto polycationic surfaces. Already mentioned is the fact that electrostatic attractions exist between the positively charged polycations and the negatively charged heparin. However, steric accessibility of heparin onto polycationic interfaces is also an important consideration. When a polycation is covalently immobilized onto a polymer surface, the polycation is relatively rigid and not laterally movable due to the intramolecular and intermolecular charge repulsions. The unfavorable steric effect restricts heparin binding onto the polycationic interfaces, particularly in the lower regions of the interfacial polycations. Therefore, heparin binding onto polycationic surfaces may be controlled by the balance between the electrostatic attraction and steric accessibility factors.
It would therefore be desirable to increase the heparin binding efficiency on polycation-immobilized surfaces by minimizing the effect of steric inaccessibility.
Objects and Brief Summary of the Invention
It is an object of this invention to provide a means of removing heparin from blood by means of polycationic attraction and binding.
It is a further object of this invention to provide means of controlling the amount of heparin in the bloodstream.
An additional object of this invention is the formation of a polymeric substrate containing polycationic ligands having primary amino groups and preferably those selected from the group consisting of polylysine (PLL), polyallylamine (PALA) or polyvinylamine (PVA) bonded through a polyethylene oxide (PEO) spacer grouping to a biocompatible polymeric substrate.
Another object of this invention is to provide a method for the binding and/or removal of heparin in blood by contacting the blood with a polymeric substrate containing polycationic ligands selected from the group consisting of polylysine (PLL), polyallylamine (PALA) or polyvinylamine (PVA) bonded through a polyethylene oxide (PEO) spacer grouping to a biocompatible polymeric substrate.
An additional object to provide a method of removing heparin from blood with a minimum loss of the plasma proteins and other components of blood.
It has now been found that compositions consisting of a polymeric substrate which has been modified to contain polycations such as polyallylamine (PALA), poly- L-lysine (PLL) or polyvinylamine (PVA) covalently bonded to the substrate through a polyethyleneoxide type spacer effectively removes heparin from blood with little or no loss of plasma proteins or other blood components. The use of PALA or PLL is most preferable with PALA being the polycation determined to be best suited for purposes of this invention.
The polycationic ligand, when covalently bound to a suitable polymeric substrate via a polyethylene oxide (PEO) spacer, provides a solution like polycationic interfacial environment. The solution like conditions are due to the increased mobility of the polycation ligand as a result of the PEO spacer. The flexibility of
the polycation attributed to the presence of the spacer at the interface of the polymer minimizes the steric inaccessibility of the heparin thereby improving the binding characteristics.
While any suitable polycation ligand rich in NH2 groups can theoretically be utilized to bind heparin, it has been found preferable to use either polyallylamine (PALA) or poly-L-lysine (PLL) as the ligand. Also, to maximize the interaction between the PEO spacer and the polymer, it has been found preferable to utilize a polymer substrate having free hydroxy groups such as cellulose or cellulose diacetate. The PEO molecule may be derivatized by functional groups, as will be discussed more in detail below, to maximize the ability of the PEO to covalently link the ligand with the polymeric substrate.
Heparin is removed from blood or other fluids by bringing the fluids in contact with the polymeric substrate material containing immobilized polycations with PEO spacers where heparin is adsorbed by the material. Heparin can be released from the immobilized polycations by treatment with a basic solution, thereby allowing the material to be reused when practical.
The substrate containing the immobilized polycationic ligands connected via the PEO spacers must present a large surface area to the blood or other fluid in order to maximize the opportunity for the heparin to come into contact with the positively charged ligands. As such, the substrates can be in the form of films, beads, honeycombs, coated surfaces, strands, filaments, and the like.
The rate of heparin binding is somewhat dependant on controlling parameters such as blood flow rates, concentration of heparin in blood and exposure time of heparinized blood to the binding substrate. The binding of heparin onto the polycationic surfaces grafted to the polymer surface via PEO spacers of molecular weight of
between about 600 and 8,000 seems to depend on the balance of several factors such as the size of the polycation ligand, the molecular weight of the PEO spacer, the mobility of the PEO and the chain length of the PEO-polycation at the interface.
PALA having molecular weights ranging from about 8,500 to about 65,000 is suitable for use in the present invention. As used herein, PALA is categorized as PALA(L) for a low molecular weight PALA having a molecular weight of between about 8,500 and 11,000 and PALA(H) for a high molecular weight PALA having a molecular weight range of about 50,000 to 65,000.
When using PALA(L) as the ligand, the maximum heparin binding was observed in the region of PEO molecular weight of between about 2000 and 4000. When using PALA(H) heparin binding did not show clear dependence on the weight of the PEO spacer due to the relatively large size of the PALA(H) ligand.
It further appears that PALA(L) interface with the PEO spacer presents a more solution-like surface than does PALA(H).
As it relates to plasma protein adsorption, it was observed that adsorption reduced with the increase in the chain length of the PEO spacer suggesting that long chain PEO spacers will minimize protein adsorption from blood and thereby improve the biocompatibility of polycationic surfaces. A composition consisting of low molecular weight PALA (M.W. 8500) immobilized onto a biopolymer surface with a PEO spacer (M.W. 3400) is believed to provide optimal heparin binding capacity with decreased protein adsorption.
The heparin removal from polycationic containing substrates is primarily due to the charge interaction between the polyanionic heparin and the polycations. No hemolysis or clotting is observed in circulating blood, suggesting the such a removal system will not cause adverse effects on blood. The system is also effective
in removing heparin from aqueous solutions other than blood.
DETAILED DESCRIPTION OF THE INVENTION
The following terminology and/or formulas will be used throughout the description when referring to substrates modified by having a polycation covalently grafted thereon.
By substrate is meant any suitable biopolymer having hydroxy groups to which the polycation may be covalently bonded, either directly or through a PEO type spacer. The substrate may be represented by the following formula:
(Formula l)
where z can be any number, where the number of OH groups is only representative of their presence and where the polymer backbone is representative of any polymer unit. In other words, Formula 1 is meant to depict any suitable biopolymer to which polycations may be covalently bonded unless a particular polymer is specifically designated. Biomedical polymers include, but are not limited to, such hydroxy containing materials as cellulose and derivatives such as cellulose diacetate (CA), poly (ethylene-vinyl alcohol) copolymers
(PEVAL), agarose and the like. Further, one skilled in the art can also utilize other biomedical polymers such as polycarbonates, silicones, acetals, polyesters, polytetrafluroethylene, polyurethane, pyrolytic carbon, nylon or other polyamides, polyacrylonitrile, polyethersulfone and the like by devising reaction sequences and linkages which provide for covalent attachment of polycations to these surfaces.
By polycation is meant a polymeric molecule having a repeating segment containing primary amino groups on
the side chain and which is positively charged at neutral pH. These may be generically referred to as polyaminocations (PAC). As stated, polyallylamine (PALA), poly-L-lysine (PLL)) and polyvinylamine (PVA) are preferred with PALA and PLL being most preferred.
PLL is a polypeptide of the formula:
which has repeating units containing primary amino groups of the formula:
wherein n is an integer of between about 200 and 240 and which becomes cationic when the e-amino gruups on the side chain become fully protonated. Its ionization depends upon the pH of the medium in which it is contained but is known to form electrostatic interactions with heparin at a neutral pH. The positive charges of PLL per molecule can be adjusted by selecting different molecular PLL weights. The molecular weight range of PLL will generally vary between about 40,000 and 50,000.
PALA is a recently commercialized polymer with primary amino groups as pendant side chains having the formula:
wherein m is an integer of between about 78 to 500, having a molecular weight of between about 8,500 and 65,000 and is prepared from polymerization of a monoallylammonium salt initiated by an azo compound. PALA is obtained commercially as a HCl salt wherein the HCl is removed by increasing the pH with NaOH. PALA has a higher positive charge density than PLL.
The terms poly(ethylene glycol) (PEG) and poly (ethylene oxide) (PEO) are used interchangeably and identify a neutral polyether of the formula:
HO-(CH2CH2O)n-H
where n is an integer of between about 13 and 180. Throughout this disclosure the term PEO will be used. PEO is extremely water soluble. Low molecular weight PEO, (less than 600) is a viscous fluid at room temperature. As the molecular weight increases, PEO becomes a waxy solid and morphology changes from amorphous to crystalline. PEO-water interaction is found to increase sharply with increasing molecular weight until a weight of about 3400 is reached and then remains constant within the 3400-20000 molecular weight range. When used as a spacer grouping it has been found that the chain mobility of PEO increases with increasing molecular weight up to about 4,000.
PLL and PALA Immobilized Directly on Polymeric surfaces
For comparison purposes PALA and PLL were both immobilized on PEVAL copolymer covalently using cyanogen bromide as a coupling agent. Cellulose diacetate and
cellulose hollow fibers could also be used because each of these materials have hydroxyl groups available after proper treatment which can be activated by BrCN. Therefore, the amino groups of PALA and PLL can be coupled directly with the hydroxyl groups on these polymeric supports.
This may be exemplified by the reaction of Formula 1 with BrCN to form a reactive intermediate imidocarbonate represented by Formula 4 as follows:
O
(Formula 4)
The imidocarbonate of Formula 4 is then reacted with either PLL or PALA in an aqueous solution to covalently link a primary amino group from a pendant PLL or PALA chain with the polymer surface as follows in
Formulas 5 and 6 respectively:
/
/
/
/
/
/
/
/
/
When the PLL or PALA polycation is covalently immobilized on the polymer surface, it is relatively rigid and not laterally movable due to the intramolecular and intermolecular charge repulsions. The relatively low binding of heparin on polycations rigidly bound may be ascribed to the steric inaccessibility of heparin into the root part of the relatively rigid polycationic interface. Therefore, heparin may not bind efficiently on polycationic directly immobilized on to polymeric surfaces.
When PALA or PLL are coupled directly onto a poly(ethylene-vinyl alcohol) (PEVAL) surface using BrCN as a coupling reagent under exactly the same experimental conditions, the PALA immobilized surface (Formula 6) demonstrates a heparin binding capacity which is about 1.3 times that of PLL (Formula 5) which is believed to be due to the higher charge density of PALA per molecule when compared with PLL. Heparin binding of PALA was 0.71 ± 0.08μg/cm2 and of PLL was 0.52 ± 0.19 μg/cm2.
Detailed Description Preferred Embodiments of the Invention
As referenced above, the primary factors affecting heparin binding onto polycationic surfaces are electrostatic attractions between the positively charged surfaces and the negatively charged heparin, and steric accessibility of heparin into polycationic interfaces.
When a polycation is covalently immobilized directly onto a polymer surface, the polycation is relatively rigid and not laterally movable due to the intramolecular and intermolecular charge repulsions.
Such unfavorable steric effect restricts heparin binding onto the polycationic interfaces, especially in the lower or 'root' regions of the interfacial polycations.
Therefore, heparin binding onto polycationic surfaces may be enhanced by the balancing of the electrostatic binding and steric accessibility factors. It has been
found that the heparin binding efficiency on polycation- immobilized surfaces is increased if the effect of the steric inaccessibility is minimized and a solution like polycationic interfacial environment is provided.
Increasing mobility of the polycation on the surface achieves a solution like interface. Polyethylene glycol (also referred to herein as polyethylene oxide "PEO") has high hydrophilicity and dynamic mobility. Considering these properties PEO is an excellent spacer between the surface and a polycation. The PEO provides a larger intermolecular gap between the polycations at the interface of the polymer surface and therefore minimizes the steric inaccessibility. Therefore, the binding properties of heparin are increased when PEO spacer molecules are inserted between the surface and the polycations.
The heparin removal system is formed by reacting a polymeric surface containing free hydroxy groups, preferably with a PEO molecule which has been derivatized to form a diacid thereby creating an ester linkage between the hydroxy groups of the surface and the carboxylic acid group of the diacid. While the following methods are not considered to be exhaustive, PEO may be derivatized to form diacids by : 1) the reaction of polyethylene oxide with succinic anhydride as shown in Formula 7; 2) the reaction of an alkoxide of polyethylene oxide with 2-halo-alkyl acetate as shown in Formula 8; and 3) the reaction of polyethylene oxide with an alkylene diacid such as azelaic acid as shown in Formula 9.
HO-(-CH2CH2O-)-nH + - O -
n=50-100
Formula 7
HO-(-CH2CH2O-)-n-OH + Na/naphthalene + Br-(CH2 )-aCO2Et
O O
( 2)a-O-( 2 2 )n ( 2)a
1
Formula 8
O O O O O O
Depending upon the method of synthesis the diacids may be generically represented by a single formula as seen in Formula 10 as follows:
O O O O
Formula 10
where d is an integer of 1 to 10, y is an integer of 0 or 1 and n is an integer of between about 10 to 200.
The diacid PEO intermediate as represented by Formula 10 is first grafted onto the surface of a polymer, preferably one containing OH groups (Formula 1), using an agent such as 1,3-dicyclohexylcarcodiimide (DCC) to esterify the carboxylic acid groups of the diacid derivatized PEO with the hydroxyl group of the polymer surface according to following sequence:
(Formula 1)
(Formula 10) x Λ J
(Formula 11)
The esterified PEO grafted onto the polymer surface, as represented by Formula 11, then has polycations, such as PLL or PALA, immobilized to the polymer by reacting the -COOH at the opposing end of the PEO with the polycation using an agent such as (3- dimethlyamino-propyl)carbodimide (EDC). Preferably the amount of polycation in the reaction solution will be in excess resulting in only one amino group of PLL or PALA per molecule reacting with each COOH group on the surface. This reaction sequence is represented as
follows resulting in PLL or PALA immobilized compositions represents by Formulas 12 and 13 as follows:
(Formula 11)
(Formula 2)
(Formula 11)
(Formula 3)
m=78-500
The final product formed contains polylysine (PLL) or polyallylamine (PAPA) separated from the surface by a spacer molecule of PEO. However, any polycation having free amino groups which can be covalently bonded to the PEO spacer may be a suitable agent and is within the scope of this invention. Therefore, the compositions of the invention may be broadly defined by the following formula 14:
where PAC stands for any suitable polyaminocation and preferably one selected from the group consisting of polyallyl amine (PALA), poly-L-lysine (PLL) or polyvinlyamine. Again, it is to be emphasized that the material upon which the spacer molecule is bonded can be any substance that has free hydroxy groups to which the PEO diacid intermediate can be esterified, for example, cellulose, cellulose acetate or a poly(ethylene vinyl alcohol) copolymer.
More particularly, the formula representing the compositions of this invention may be further simplified for purposes of claiming. The structures of the PEO spacer, and the PALA and PLL ligands are given in detail above. All have certain repeating units within their respective molecular structures and hence, with the formulas established, it is the molecular weights of these units which determines their functionality in the binding of heparin. Therefore the following formula will be referred to in the claims:
Substrate-OC-PEO-CNH-PAC
where Substrate is the same as Formula 1, -OC(O)-PEO- C(O)- has the same meaning as the PEO diacid of Formula 10 and -NH-PAC is the polyaminocation ligand and is preferably the PLL of Formula 2 or the PALA of Formula 3. Obviously, from this simplified definition any of the above formulas and/or structures can be readily determined by knowledge of the molecular weights of the PEO spacer or polycation ingredients and the identity of the specific substrate.
The following examples show a preferred means in which polycations are immobilized onto a polymeric surface with PEO spacers using a reaction sequence to covalently link the amino groups of polycations with carboxyl groups of derivatized PEO derivatives.
Example 1
Synthesis of PEO Dicarboxylic Acids
This examples describes the derivatization of PEO with succinic anhydride to prepare PEO derivatives having carboxyl end groups according to the reaction sequence shown in Formula 7. The hydroxyl end groups of PEO (having molecular weights of 600, 2000, 3400, and 8000) were reacted with succinic anhydride in dioxane using 4-Dimethylaminopyridine (DMAP) and triethylamine (TEA) as catalysts according to the above reaction sequence. Succinic anhydride (20 mmol), 4- Dimethylaminopyridine (10 mmol) and triethylamine (TEA) (10 mmol) were dissolved in 20 ml of dioxane and added to a solution of 5 mmol of polyethylene oxide (PEO) (10 mmmol of OH groups) in 50 ml of dioxane. The mixture was stirred for 12 hr at 60° C. Most of the dioxane was then removed by a rotavapor. The residue was dissolved by dichloromethane and precipitated by ether. The products were dissolved and precipitated twice from dichloromethane/ether and then vacuum dried.
The terminal carboxylic acid groups of polyethylene oxide (PEO) diacids (M. W. 600-8000) was determined by non-aqueous titration. PEO diacids (5 x 10-4 mol) were
dissolved in dioxane and titrated by sodium methoxide (0.1 N) in methanol-benzene (2.8) using 0.2% thymol blue as an indicator. The pure polyethylene oxide (PEO) in dioxane was used as a blank. The amount of sodium methoxide consumed by PEO diacid gave the information on the amount of carboxylic acid groups at two ends of polyethylene oxide (PEO).
Example 2
This example describes the preparation of a cellulose acetate substrate to which is attached the PEO-diacid spacer prepared according to Example 1.
Preparation of Cellulose Acetate Film
Cellulose acetate was dissolved in acetone to make a 10% solution. A casting knife was used to make a film with 0.8 mm thickness on a glass plate and allowed to air dry. The dried cellulose film was peeled off by rinsing the plate with distilled water.
Reaction of PEO Diacid with Cellulose Acetate Film
The cellulose acetate (CA) film (1000 cm2) was immersed in dichloromethane:toluene solvent (5:5) overnight, then 9x10-4 mol of PEO diacid of Example 1 and 9X10-1 mol of 4-dimethylaminopyridine (DMAP) were added into the solution and stirred at 4°C for one hour. A 5 ml aliquot of 9X10-4 mole of DCC in dichloromethane:toluene (5:5) was added dropwise to the reaction mixture and stirred for an additional 1 hour at 4°C. The whole solution was moved to 22 °C and allowed to stand for 48 hr. After the reaction, the CA-PEO films thus formed were washed with toluene and vacuum dried at 40°C for 72 hours to remove residual toluene. The resulting product was characterized by IR spectroscopy and differential scanning calorimetry and is representative of that shown in Formula 11 where n is 87.
Reaction of PEO Diacid with CA Solution
Cellulose acetate particles were dissolved in acetone and reacted with polyethylene glycol diacid (M. W. 600) in CH2Cl2 using the same procedures as described above. After the reaction, the solution was filtered to remove the precipitate (side product N, N'-dicyclohexyl- carbodimide). The filtrated solution was then precipitated in ether and vacuum dried. The solid residue was washed with distilled water to remove the excess PEO diacid. The resulting product was characterized by IR spectroscopy and differential scanning calorimetry and is representative of that shown in Formula 11 where n is 87. Determination of PEO on CA Surfaces
The amount of PEO coupled onto CA film surfaces was determined by acid-base back titration of its free end of carboxylic acid. The coupled film was thoroughly washed with distilled water and then immersed in distilled water (10 ml). Sodium hydroxide (0.01 N) was added to adjust the pH above 7.0. The solution and film were titrated potentiometrically with 0.01 N hydrochloric acid and the pH was monitored by a Corning pH Meter. CA film without PEO was used as blank. The amount of HCl consumed by PEO grafted film between the second equivalent point subtracted from the amount of HCl used by the blank at the same pH gave the amount of carboxylic acid groups, hence the PEO content on CA film. The results are shown in the table in following Example 3.
Example 3
This example describes the reaction of polyallyl amine with the CA-PEO film formed in Example 2.
Reaction of PALA with CA-PEO Film
CA-PEO-COOH film prepared as described above (1000 cm2) was immersed in water. PALA (2 x10-4 mol) was added into the film suspension and stirred at 4°C for 1 hr.
EDC (2.5x10-4 mol) in 10 ml of distilled water was added dropwise to the solution and the pH was adjusted to 5. The solution was then stirred for an additional 1 hr. at 4°C. The whole solution was moved to 22°C and allowed to stand for 24 hr. Two additional volumes of EDC were added to the solution at 3 and 6 hr during the reaction. After the reaction was completed, the CA-PEO-PALA films were washed with distilled water. The CA film contained immobilized PALA connected to the film surface via PEO spacers as shown in Formula 13. Both low molecular weight PALA(L) and high molecular weight PALA(H) were immobilized with varying PEO molecular weight spacers.
The content of amino groups from PALA immobilized on the surface was determined by acid-base potentiometric back titration and also by spectroscopy analysis. At pH < 7, all the -NH2 groups are changed to - NH3 + which can be potentiometrically titrated by NaOH. The difference in the amounts of NaOH used between the CA-PEO-PALA and a blank CA gives the amounts of the amino groups on the surface. The results, measured in surface concentrations of 10-8 mole/cm2, are shown in the following table:
* **
The amount of amino groups on PALA(H) immobilized surfaces is about 2-3 times higher than that on PALA(L) surfaces.
A similar procedure to that described above can be used to immobilize PLL onto a CA-PEO film to prepare a product as shown in Formula 12.
Example 4
Heparin Binding in Aqueous Solution
To evaluate the PEO spacer effects on heparin binding efficiency, CA-PEO-PALA films (240 cm2) were placed in 10 ml of 40μg/ml heparin solution (0.1 N Sodium carbonate buffer solution or saline) with shaking for 1 hr. The difference of heparin amount before and after binding gave the net amount heparin bound on the surfaces. CA-glutaric acid-PALA films was also evaluated as a control and compared with CA-PEG-PALA surfaces. The glutaric acid spacer did not provide sufficient linkage space to have any affect on the binding capacity of the PALA.
The amount of heparin on PALA(L) (molecular weight 8,500) immobilized with PEO spacers of varying molecular weight is shown in the following table with a concentration of immobilized PALA on the cellulose acetate surface being given in concentrations of 10-10 mole/cm2:
The maximum binding of heparin occurred on the PALA(L)-immobilized surfaces with PEO(2K) or PEO (3.4K) spacers. The heparin binding capacities (2.35 ± 0.03 μg/cm2 and 2.34±0.01 μg/cm2 for PEO(2K) or PEO (3.4 K), respectively) at the maximum binding region were increased 3.5 fold as compared with the PALA(L) surface
without PEO spacer (0.68 ± 0.09). To further investigate the PEO effects on the heparin binding, the plot of mole ratio of heparin bound (based on M. W. 5000) to PALA(L) on the surface versus the molecular weight of PEO spacers was drawn. It was found that the heparin binding capacity depended on the chain length of PEO. The maximum synergistic effect for heparin binding on lower molecular weight of PALA surfaces was obtained with the PEO spacers having M.W. 2000 and M.W.3400. The curve (not shown herein) appeared as a reverse bell shape along the X axis: low heparin binding efficiency with the control or PEO(0.6K) with significantly increased efficiency with PEO(2K) and PEO (3.4K), and then a decrease in binding efficiency with PE0(8K). When the molecular weight of PEO was greater than 6000, the segmental motions of PEO was found to be independent of molecular weight of PEO. Other supportive evidence is that the cooperativity of water-PEO interactions increased with the increase in the molecular weight of PEO until a molecular weight of about 3400 was reached.
The amount of heparin on PALA(H) (molecular weight 50,000) immobilized with PEO spacers of varying molecular weight is shown in the following table with a concentration of immobilized PALA on the cellulose acetate surface being given in concentrations of 10-11 mole/cm2:
For higher M.W. PALA (PALA(H), 50,000-immobilized surfaces, the effects of PEO on heparin binding differed from PALA(L) -immobilized surfaces. Heparin binding efficiency of PALA(H) surfaces with PEO(0.6K) spacer (0.87 ±0.09 μg/cm2,) increased 1.8-fold when compared to PALA(H) surface without PEO spacer. Nevertheless, increase in molecular weight of PEO spacers did not affect heparin binding on PALA(H) surfaces. The maximum heparin binding region was not observed in the plot of the mole ratio of heparin bound to PALA(H) surface against the molecular weight of PEO spacers.
When the PEO synergistic effects on heparin interaction with PALA(H) and PALA(L)-immobilized surfaces were compared, it was found that the PALA(L) was more sensitive to the length or M.W. of PEO spacers than the PALA(H) surfaces. The possible explanation is that for PALA(H)-immobilized surfaces, PEO only slightly enhanced the mobility of PALA(H) due to its relatively large molecular size. However, for PALA(L)-immobilized surfaces, PEO not only enhanced the mobility, but also significantly increased the relative chain length of the dynamic motion part at the PEO-PALA(L) interface. Consequently, the PEO-PALA(L) interface was more solution like and less steric restriction than the PEO- PALA(H) interface. For the PALA(L)-immobilized surfaces, when glutaric acid was used to link PALA(L) with the CA film, no spacer effect was considered due to its short chain. Therefore, heparin binding efficiency was low due to the rigid PALA(L) at the interface. With PEO(0.6K) as a spacer, despite the increased mobility of PALA(L) at the interface, the short chain length of PALA(L)-PEO (0.6K) at the interface could not enhance heparin binding. This minimum chain length requirement at the interface may be ascribed to the relatively large size of the heparin macromolecule. When PEO M.W. was increased to 2000 or 3400, the mobility of PALA(L) at interfaces was further increased, as well as the whole
chain length of PALA-PEO was elongated. As the result of both enhancement effects, the heparin binding efficiency increased dramatically. If the chain length of PEO further increased to molecular weight 8000, however, the mobility of PEO did not increase because of the reasons already mentioned above. The positive charges of PALA(L) may also be partially masked by the long chain PEO which may possibly entangle with or bend down to PALA(L).
For the high M.W. PALA-immobilized surfaces, however, PEO(0.6K) increased slightly the mobility of
PALA(H) at the interface as compared with the PALA(H) immobilized surface without PEO spacer. At the same time, the chain length of the PALA(H)- PEO(0.6K) at the interface was already long enough. Therefore, the heparin binding efficiency somewhat increased. Even if the chain length of PEO was further increased (PEO(2K),
PEO3.4K) and PEO(8K)), however, the mobility of PALA(H) may not further increase due to the molecular size of PALA(H). Consequently, heparin binding efficiency remained almost the same as that of PEO(0.6K). Compared to the PALA(L), the heparin binding did not drop down in the PEO(8K) region for PALA(H)-immobilized surface, which may be credited to the long chain of the high molecular weight PALA. It may make PEO(8K) difficult to mask the positive charges of high molecular weight of
PALA. These results suggest that not only does the PEO mobility improve heparin binding on PALA surface, but also the PALA chain length at the interface may also play a role in heparin binding efficiency.
Example 5
Heparin Binding in Blood
CA-PEO (2K) -PALA(L) film was immersed in 1 ml of the heparinized bovine plasma or whole blood (40μg heparin/ml blood, 2% of 35S-labeled heparin). After incubation for 1 hr, the film was rinsed with distilled water and 1 ml of NaOH solution was added. After 5 min
shaking, CytoScint cocktail (15ml) was added. The solution was mixed well on a vortex shaker and the radioactivity was counted.
Heparin binding was also evaluated in serum. CA- PEO (2K)-PALA(L) film was immersed in 1:10 diluted serum solution containing heparin (40μg heparin/ml serum solution). After incubation for 1 hr., 0.5ml of solution was taken out for Azure II colorimetric assay.
The amount of heparin bound on CA-PEO(2K)-PALA(L), CA-PEO(2K)-PALA(H), CA-glutaric acid-PALA(L), and CA- glutaric acid-PALA(H) membranes in bovine serum was compared with the corresponding heparin binding amount in aqueous solution. The comparison did not show significant difference between these two media. The amount of heparin binding in bovine plasma or whole blood was determined by counting the radioactivity of 35S-heparin on the film. The amount of heparin bound on the CA-PEO(2K)-PAL-(L) film from plasma or whole blood was compared with the corresponding heparin bound amount in PBS using tracer 35S-heparin, no significant differences in heparin binding amount among the three media were observed. The data shows blood components do not affect heparin binding on CA-PEO-PALA surfaces.
Example 6
Protein Adsorption
Iodine-125 labeled bovine albumin was used as a model protein to study protein adsorption on CA-PEO-PALA surfaces using low molecular weight PALA and PEO spacers varying in molecular weight of from 600 (0.6K) to 8,000 (8K). The concentration of albumin in serum was determined by the bromcresol green method. Different CA-PEO-PALA films (8 cm2) (CA-glutaric acid-PALA(L) (control), CA-PEO(0.6K)-PALA(L), CA-PEO(2K)-PALA(L), CA- PEO(3.4K)-PALA(L), CA-PEO(8K)-PALA(L)) were immersed in the serum solutions (1 ml) which had 50% of normal serum. The film contained solutions were shaken for 1 hr and then rinsed with distilled water and saline until
no radioactivity could be detected in the wash. The films were transferred to vials and the radioactivity on the film was counted by Minaxi Gamma Counter (auto-gamma 5000 series, Packard Instrument Company, Downers Grove, IL). The amount of albumin adsorbed (μg/cm2) of the film surfaces is given in the following table:
It is readily apparent that the minimum albumin adsorption was found on the PALA surfaces with PEO(3.4K) and PEO(8K) spacers. There was no significant difference in albumin adsorption between PEO(3.4K) and
PEO(8K) spacers.
Although the above examples were carried out using PALA as the polycation, PLL could have been utilized with comparable results.
Both PALA and PLL are structurally similar in having primary amino groups on the side chain and both being positively charged at neutral pH. PALA has a higher charge density per molecule than PLL due to the smaller repeat unit. Empirical results show that both PALA and PLL have similar heparin binding capacities.
Comparison of average pKa of PALA and PLL indicates that the basic strength of PALA is slightly lower than that of PLL but the difference was not significant. The repulsive interactions of the intramolecular amino groups on the PALA chain is greater than that of PLL which may be attributed to the higher charge density per molecule of PALA than PLL. The greater intramolecular force between functional amino groups on PALA also translates into the fact that changes of pKa value of PALA is more sensitive than to the changes of pH than
with PLL. Another similarity with PALA and PLL is that the degree of ionization is similar at about neutral pH. The pKa of PLL is lightly higher than that of PALA inferring that he interaction between PLL and polyanions such as heparin may be somewhat stronger than that of PALA. However, the higher positive charge density of PALA per molecule when compared with PLL suggests that PALA may actually bind more heparin than PLL.
In view of the above, the criteria for selecting a polycation as a heparin binding reagent are (a) capability of binding heparin, (b) functional groups which can be covalently grafted onto polymeric surfaces and (c) commercial availability at a reasonable price. Any polycation having primary amino groups is considered to be a candidate for use in this invention due to the likelihood of various chemical reactions with the free amino groups. Inclusive of polycations which are currently commercially available and have free amino groups are PLL, PALA and PVA. The high price of PLL limits its practical usage. Furthermore, the terminal
COOH group on this amino acid makes it more difficult to covalently bond to the PEO spacer by linking the amino groups on the PLL chain with the COOH groups of the derivatized PEO. This creates the possibility of self- cyclization between the pendant amino groups and the carboxyl end group of the same PLL molecule. Neither PALA nor polyvinylamine have this terminal COOH problem. However, that does not remove the possibility of utilizing PLL in the present invention. The difficulties encountered merely make the PALA the preferred polycation to use because it does not possess carboxyl groups. The PVA molecule has not been utilized in tests but is also believed to be functional in the present invention.
In view of the above, it was deemed that PALA would be the most practical and best polycation embodiment of the invention to illustrate. Therefore, while the
invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various modifications, changes, omissions, and substitutions can be made without departing from the spirit of the invention. It is intended, therefore, that the invention be limited only by the scope of the following claims.
To simplify claim terminology certain shortened definitions will be utilized in view of the detailed description given above. The substrate of Formula 1 will simply be referred to as "Substrate".
Claims
1. A composition having the formula:
O O
Substrate-OC-PEO-CNH-PAC
where Substrate represents any suitable biopolymer to which polycations may be covalently bonded through a spacer grouping; -OC(O)-PEO-C(O)- is a polyethylene oxide polymer having a molecular weight of between about 600 and 8000; and -NH-PAC represents any suitable polyaminocation which contains a positive charge at a neutral pH.
2. A composition according to Claim 1 wherein - NHPAC is a member selected from the group consisting of polyallylamine (PALA), poly-L-lysine (PLL) and polyvinylamine (PVA).
3. A composition according to Claim 2 wherein - NHPAC is a member selected from the group consisting of PALA and PLL.
4. A composition according to Claim 3 wherein - NHPAC is PLL.
5. A composition according to Claim 3 wherein - NHPAC is PALA having a molecular weight of between about 8,500 and 65,000.
6. A composition according to Claim 5 wherein the PALA is PALA(L) having a molecular weight of between about 8,500 and 11,000.
7. A composition according to Claim 6 wherein the polyethylene oxide polymer has a molecular weight of about 2000 to 3400.
8. A composition according to Claim 7 wherein PALA has a molecular weight of about 8,500.
9. A composition according to Claim 5 wherein PALA is PALA(H) having a molecular weight of between about
50,000 and 65,000.
10. A composition according to Claim 1 wherein Substrate is a member selected from the group consisting of cellulose, cellulose diacetate, poly(ethylene-vinyl alcohol) and agarose.
11. A method for removing heparin from an aqueous solution containing the same which comprising (a) providing a composition of the formula:
O O
Substrate-OC-PEO-CNH-PAC where Substrate represents any suitable biopolymer to which polycations may be covalently bonded through a spacer grouping; -OC(O)-PEO-C(O)- is a polyethylene oxide polymer having a molecular weight of between about 600 and 8000; and -NH-PAC represents any suitable polyaminocation which contains a positive charge at a neutral pH; (b) bringing said solution containing heparin into contact with said composition at a neutral pH causing heparin to bind to said polyaminocation and (c) removing said solution depleted of heparin from contact with said composition.
12. A method according to Claim 11 wherein -NHPAC is a member selected from the group consisting of polyallylamine (PALA), poly-L-lysine (PLL) and polyvinylamine (PVA).
13. A method according to Claim 12 wherein -NHPAC is a member selected from the group consisting of PALA and PLL.
14. A method according to Claim 13 wherein -NHPAC is PLL.
15. A method according to Claim 13 wherein -NHPAC is PALA having a molecular weight of between about 8,500 and 65,000.
16. A method according to Claim 5 wherein the PALA is PALA(L) having a molecular weight of between about
8,500 and 11,000.
17. A method according to Claim 16 wherein the polyethylene oxide polymer has a molecular weight of about 2000 to 3500.
18. A method according to Claim 17 wherein PALA has a molecular weight of about 8,500.
19. A method according to Claim 15 wherein PALA is PALA(H) having a molecular weight of between about 50,000 and 65,000.
20. A composition according to Claim 11 wherein Substrate is a member selected from the group consisting of cellulose, cellulose diacetate, poly(ethylene-vinyl alcohol) and agarose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82271592A | 1992-01-21 | 1992-01-21 | |
US822,715 | 1992-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993014127A1 true WO1993014127A1 (en) | 1993-07-22 |
Family
ID=25236770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/000678 WO1993014127A1 (en) | 1992-01-21 | 1993-01-19 | Method and composition for heparin binding using polyaminocations covalently immobilised on polymeric surfaces with polyethylene oxide spacers |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3592693A (en) |
WO (1) | WO1993014127A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995024437A1 (en) * | 1994-03-11 | 1995-09-14 | Hoechst Aktiengesellschaft | Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents |
WO1998022162A1 (en) * | 1996-11-20 | 1998-05-28 | Biocompatibles Limited | Biocompatible compositions |
WO1999001195A1 (en) * | 1997-07-01 | 1999-01-14 | Terumo Cardiovascular Systems Corporation | Removal of biologically active agents |
US5891196A (en) * | 1997-04-16 | 1999-04-06 | Baxter International Inc. | Method for actively binding heparin to crosslinked biological tissues |
US6143354A (en) * | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
US6303179B1 (en) | 1999-02-08 | 2001-10-16 | Medtronic, Inc | Method for attachment of biomolecules to surfaces through amine-functional groups |
EP1676581A3 (en) * | 1993-08-11 | 2008-12-03 | Genzyme Corporation | Polymer compositions for use in therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4720512A (en) * | 1986-03-24 | 1988-01-19 | Becton, Dickinson And Company | Polymeric articles having enhanced antithrombogenic activity |
US5043278A (en) * | 1986-03-28 | 1991-08-27 | Toray Industries, Inc. | Physiologically-active substance fixed to a thin fiber carrier with an alkylene oxide chain |
-
1993
- 1993-01-19 AU AU35926/93A patent/AU3592693A/en not_active Abandoned
- 1993-01-19 WO PCT/US1993/000678 patent/WO1993014127A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4720512A (en) * | 1986-03-24 | 1988-01-19 | Becton, Dickinson And Company | Polymeric articles having enhanced antithrombogenic activity |
US5043278A (en) * | 1986-03-28 | 1991-08-27 | Toray Industries, Inc. | Physiologically-active substance fixed to a thin fiber carrier with an alkylene oxide chain |
Non-Patent Citations (5)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 112, issued 1990, NAGAOKA et al., "The Activity of Immobilized Heparin via Long Poly(Ethylene Oxide) Spacers", see page 414, Abstract No. 125146q; & J. BIOACT. COMPAT. POLYM., 1989, 4(4), 323-332. * |
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, Vol. 22, issued 1988, K.D. PARK et al., "Heparin Immobilization onto Segmented Polyurethaneurea Surfaces - Effect of Hydrophilic Spacers", pages 977-992. * |
THROMBOSIS RESEARCH, Vol. 20, Number 5/6, issued 1980, S.F. MOHAMMAD et al., "Quantitative Removal of Heparin from Plasma and other Aqueous Solutions by Affinity Absorption on Poly(L-Lysine)-Sepharose 4B", pages 599-609. * |
THROMBOSIS RESEARCH, Vol. 41, Number 1, issued 1986, A.M. CUMMING et al., "In Vitro Neutralization of Heparin in Plasma Prior to the Activated Partial Thromboplastin Time Test: An Assessment of Four Heparin Antagonists and Two Anion Exchange Resins", pages 43-56. * |
ZEITSCHRIFT FUR NATURFORSCHUNG, Vol. 42c, issued 1987, E. BAYER et al., "Synthese von Immobilisierten Peptidfragmenten an Polystyrol-Polyoxyethylen zur Affinitatschromatographie", pages 455-460. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1676581A3 (en) * | 1993-08-11 | 2008-12-03 | Genzyme Corporation | Polymer compositions for use in therapy |
WO1995024437A1 (en) * | 1994-03-11 | 1995-09-14 | Hoechst Aktiengesellschaft | Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents |
US5817742A (en) * | 1994-03-11 | 1998-10-06 | Hoechst Aktiengesellschaft | Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents |
WO1998022162A1 (en) * | 1996-11-20 | 1998-05-28 | Biocompatibles Limited | Biocompatible compositions |
US6432314B1 (en) | 1996-11-20 | 2002-08-13 | Biocompatibles Limited | Anion exchange materials and processes |
US5891196A (en) * | 1997-04-16 | 1999-04-06 | Baxter International Inc. | Method for actively binding heparin to crosslinked biological tissues |
WO1999001195A1 (en) * | 1997-07-01 | 1999-01-14 | Terumo Cardiovascular Systems Corporation | Removal of biologically active agents |
US6143354A (en) * | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
US6303179B1 (en) | 1999-02-08 | 2001-10-16 | Medtronic, Inc | Method for attachment of biomolecules to surfaces through amine-functional groups |
Also Published As
Publication number | Publication date |
---|---|
AU3592693A (en) | 1993-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5134192A (en) | Process for activating a polymer surface for covalent bonding for subsequent coating with heparin or the like | |
He et al. | Graphene oxide based heparin-mimicking and hemocompatible polymeric hydrogels for versatile biomedical applications | |
Wang et al. | Layer by layer assembly of sulfonic poly (ether sulfone) as heparin-mimicking coatings: scalable fabrication of super-hemocompatible and antibacterial membranes | |
KR100525604B1 (en) | Applied to medical materials of sulfones, ketones and esters containing polyalkyl ether units | |
Yang et al. | Protein adsorption and platelet adhesion of polysulfone membrane immobilized with chitosan and heparin conjugate | |
WO1987006007A1 (en) | Immobilized physiologically active material | |
Dang et al. | Heparin as a molecular spacer immobilized on microspheres to improve blood compatibility in hemoperfusion | |
US6929955B2 (en) | Interactive system for presenting and eliminating substances | |
CN101479320A (en) | Tissue adhesives with modified elasticity | |
JP2004512397A (en) | Hydrophobic multi-complex heparin conjugate, production method and use thereof | |
Huang et al. | Heparin-like chitosan hydrogels with tunable swelling behavior, prolonged clotting times, and prevented contact activation and complement activation | |
Liu et al. | Enhanced biocompatibility and antibacterial property of polyurethane materials modified with citric acid and chitosan | |
WO2020181642A1 (en) | Preparation method for ionic bond-covalent bond synergy-based surface heparinized anticoagulant medical device | |
Raut et al. | Engineering biomimetic polyurethane using polyethylene glycol and gelatin for blood-contacting applications | |
WO1993014127A1 (en) | Method and composition for heparin binding using polyaminocations covalently immobilised on polymeric surfaces with polyethylene oxide spacers | |
JP5404413B2 (en) | Polyurethane derivative and filter material for leukocyte removal using the same | |
US5416198A (en) | Selective sorbent removal system using polycation activated substrates | |
JPH05507298A (en) | Non-thrombogenic glycosaminoglycan copolymer | |
JP4925581B2 (en) | Resin with fluid compatibility and biocompatibility | |
Piao et al. | Synthesis and characterization of poly (dimethylsiloxane)-poly (ethylene oxide)-heparin CBABC type block copolymers | |
Ma et al. | Interaction of heparin with polyallylamine‐immobilized surfaces | |
JPH0536065B2 (en) | ||
JP4121205B2 (en) | Method for producing polyalkyl ether / polyaryl ether sulfone copolymer having excellent antithrombotic properties | |
JPH0119811B2 (en) | ||
Petrini et al. | Novel Poly (urethane-aminoamides): an in vitro study of the interaction with heparin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA DE FI GB HU JP KP KR LK MG MN MW NO PL RO RU SD |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |